BriaCell Therapeutics Corp. WarrantBCTXW
About: BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
Employees: 12
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
75% more funds holding
Funds holding: 4 [Q4 2024] → 7 (+3) [Q1 2025]
3.84% more ownership
Funds ownership: 1.26% [Q4 2024] → 5.11% (+3.84%) [Q1 2025]
88% less capital invested
Capital invested by funds: $129K [Q4 2024] → $15.1K (-$114K) [Q1 2025]
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Research analyst outlook
We haven’t received any recent analyst ratings for BCTXW.
Financial journalist opinion
We haven’t received any recent news articles for BCTXW.